E Ang, MK Lawrence, CR Heilmann, JA … - Diabetes Technology …, 2009 - liebertonline.com Abstract Background: Long-term safety and efficacy of AIRÒ inhaled insulin (Eli Lilly and
Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., Cambridge, MA) in patients
with diabetes and concomitant lung disease remain to be established. Methods: This ... Cited by 1 - Related articles - All 2 versions
A de la Pena, M Seger, K Rave, L Heinemann … - Diabetes Technology …, 2009 - liebertonline.com Abstract Background: In order to assess pharmacokinetic (PK) and glucodynamic (GD) attributes
relevant to the end user of an inhaled insulin, this study examined the exposure and GD effect
of doses of AIRÒ inhaled insulin (Eli Lilly and Co., Indianapolis, IN) (AIR is a registered ... Cited by 1 - Related articles - All 3 versions
L Zhi-hong, C Ying-li, LI Fang-ping, YAN Xiang, LU … - Chinese Medical Journal, 2008 - cmj.org Background A new inhalable insulin aerosol (Inh-Ins) was developed in China. The aim of this
multicenter clinical study was to evaluate the efficacy and safety of this new Inh-Ins as a treatment
of type 2 diabetes. Regular porcine insulin (RI) was used as a control. Methods This study ... Related articles - Cached - All 6 versions
C Passey, SP Bhardwaj, DK Majumdar - Current Drug Delivery, 2009 - ingentaconnect.com Abstract: Pulmonary insulin delivery is steadily emerging as a promising solution for the treatment
of diabetes mellitus. The large as well as thin absorptive area of the lungs has not been explored
until now for the treatment of systemic disease like diabetes. With an understanding of the ... Related articles - All 2 versions